Radiation Therapy

American Society for Radiation Oncology has issued a guideline on use of radiation therapy to treat patients with brain metastases.

CHICAGO — Lutetium Lu 177 vipivotide tetraxetan is a viable option for certain men with advanced prostate cancer, according to study results presented at ASCO Annual Meeting.

Acupuncture benefitted patients with head and neck cancer who had radiation-induced xerostomia, according to study results presented at ASCO Annual Meeting.

CHICAGO — Patients aged 55 years or older with low-grade luminal A breast cancer who receive endocrine therapy can safely avoid radiotherapy after breast-conserving surgery, according to a prospective study presented at ASCO Annual Meeting.

CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results presented at ASCO Annual Meeting.

CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.

Esophageal-sparing intensity-modulated radiotherapy did not significantly improve esophageal quality of life but reduced incidence of symptomatic esophagitis among patients with advanced non-small cell lung cancer.

Although much remains unknown about the impact of COVID-19 on people with cancer, the impact on screening is becoming clearer.

The addition of androgen deprivation therapy to radiotherapy improved survival outcomes among patients with localized prostate cancer, according to study results published in The Lancet Oncology.

Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.